Literature DB >> 12742201

Barrett's esophagus can and does regress after antireflux surgery: a study of prevalence and predictive features.

Richard R Gurski1, Jeffrey H Peters, Jeffrey A Hagen, Steven R DeMeester, Cedric G Bremner, Parakrama T Chandrasoma, Tom R DeMeester.   

Abstract

BACKGROUND: To investigate the factors leading to histologic regression of metaplastic and dysplastic Barrett's esophagus (BE). STUDY
DESIGN: The study sample consisted of 91 consecutive patients with symptomatic Barrett's esophagus. Pre- and posttreatment endoscopic biopsies from 77 Barrett's patients treated surgically and 14 treated with proton pump inhibitors (PPI) were reviewed. An expert pathologist confirmed the presence of intestinal metaplasia (IM) with or without dysplasia. Posttreatment histology was classified as having regressed if two consecutive biopsies taken more than 6 months apart plus all subsequent biopsies showed loss of IM or loss of dysplasia. Clinical factors associated with regression were studied by multivariate analysis, as was the time course of its occurrence.
RESULTS: Histopathologic regression occurred in 28 of 77 patients (36.4%) after antireflux surgery and in 1 of 14 patients (7.1%) treated with PPIs alone (p < 0.03). After surgery, regression from low-grade dysplastic to nondysplastic BE occurred in 17 of 25 patients (68%) and from IM to no IM in 11 of 52 (21.2%). Both types of regression were significantly more common in short (< 3 cm) than long (> 3 cm) segment Barrett's esophagus; 19 of 33 (58%) and 9 of 44 (20%) patients, respectively (p = 0.0016). Eight patients progressed, five from IM alone to low-grade dysplasia and three from low- to high-grade dysplasia. All those who progressed had long segment BE. On multivariate analysis, presence of short segment Barrett's and type of treatment were significantly associated with regression; age, gender, surgical procedure, and preoperative lower esophageal sphincter and pH characteristics were not. The median time of biopsy-proved regression was 18.5 months after surgery, with 95% occurring within 5 years.
CONCLUSIONS: This study refutes the widely held assumption that once established, Barrett's esophagus does not change. More than one-third of patients with visible segments of Barrett's esophagus undergo histologic regression after antireflux surgery. Regression is dependent on the length of the columnar-lined esophagus and time of followup after antireflux surgery.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12742201     DOI: 10.1016/S1072-7515(03)00147-9

Source DB:  PubMed          Journal:  J Am Coll Surg        ISSN: 1072-7515            Impact factor:   6.113


  33 in total

Review 1.  Barrett's esophagus with high-grade dysplasia: focus on current treatment options.

Authors:  Leonidas Lekakos; Nikolaos P Karidis; Dimitrios Dimitroulis; Christos Tsigris; Gregory Kouraklis; Nikolaos Nikiteas
Journal:  World J Gastroenterol       Date:  2011-10-07       Impact factor: 5.742

Review 2.  Barrett's esophagus.

Authors:  Jeffrey H Peters; Jeffrey A Hagen; Steven R DeMeester
Journal:  J Gastrointest Surg       Date:  2004-01       Impact factor: 3.452

Review 3.  How should Barrett's ulceration be treated?

Authors:  J H Peters; K K Wang
Journal:  Surg Endosc       Date:  2004-01-12       Impact factor: 4.584

4.  Laparoscopic treatment of Barrett's esophagus: long-term results.

Authors:  L Biertho; B Dallemagne; J-M Dewandre; C Jehaes; S Markiewicz; B Monami; C Wahlen; J Weerts
Journal:  Surg Endosc       Date:  2006-11-16       Impact factor: 4.584

Review 5.  Potent gastric acid inhibition in the management of Barrett's oesophagus.

Authors:  Angel Lanas
Journal:  Drugs       Date:  2005       Impact factor: 9.546

6.  Regression of low-grade noninvasive neoplasia in barrett's epithelium: should we lower our guard?

Authors:  Giovanni Zaninotto; Massimo Rugge
Journal:  Ann Surg       Date:  2007-02       Impact factor: 12.969

7.  Efficacy of Nissen fundoplication versus medical therapy in the regression of low-grade dysplasia in patients with Barrett esophagus: a prospective study.

Authors:  Mauro Rossi; Marco Barreca; Nicola de Bortoli; Cristina Renzi; Stefano Santi; Alessandro Gennai; Massimo Bellini; Francesco Costa; Massimo Conio; Santino Marchi
Journal:  Ann Surg       Date:  2006-01       Impact factor: 12.969

8.  Histologic and clinical outcome after laparoscopic Nissen fundoplication for gastroesophageal reflux disease and Barrett's esophagus.

Authors:  V Ozmen; E Sen Oran; E Gorgun; O Asoglu; A Igci; M Kecer; F Dizdaroglu
Journal:  Surg Endosc       Date:  2005-12-09       Impact factor: 4.584

Review 9.  Antireflux surgery for dysplastic Barrett.

Authors:  Marco E Allaix; Marco G Patti
Journal:  World J Surg       Date:  2015-03       Impact factor: 3.352

Review 10.  The Nissen fundoplication: indication, technical aspects and postoperative outcome.

Authors:  H Wykypiel; G J Wetscher; P Klingler; K Glaser
Journal:  Langenbecks Arch Surg       Date:  2004-09-04       Impact factor: 3.445

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.